Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Acquired by Barclays PLC

Barclays PLC raised its holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) by 311.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,175 shares of the company’s stock after buying an additional 63,702 shares during the period. Barclays PLC owned about 0.12% of Ovid Therapeutics worth $98,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Driehaus Capital Management LLC acquired a new stake in Ovid Therapeutics in the second quarter valued at $1,077,000. FMR LLC raised its stake in Ovid Therapeutics by 1,907.4% in the third quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after buying an additional 47,723 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after buying an additional 215,189 shares in the last quarter. GSA Capital Partners LLP raised its stake in Ovid Therapeutics by 118.0% in the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after buying an additional 141,002 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Ovid Therapeutics in the third quarter valued at $102,000. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Ovid Therapeutics Stock Down 5.5 %

OVID opened at $0.91 on Thursday. The business’s 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.06. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.66 and a current ratio of 5.66. Ovid Therapeutics Inc. has a one year low of $0.68 and a one year high of $4.10. The stock has a market capitalization of $64.61 million, a P/E ratio of -1.94 and a beta of 0.34.

Ovid Therapeutics (NASDAQ:OVID) last posted its earnings results on Tuesday, November 12th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.15 million. Analysts anticipate that Ovid Therapeutics Inc. will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.04.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.